Definium Therapeutics (NASDAQ:DFTX) CEO Robert Barrow Sells 29,208 Shares

Definium Therapeutics, Inc. (NASDAQ:DFTX) CEO Robert Barrow sold 29,208 shares of the company’s stock in a transaction on Thursday, June 25th. The stock was sold at an average price of $45.03, for a total transaction of $1,315,236.24. Following the transaction, the chief executive officer owned 1,098,246 shares of the company’s stock, valued at $49,454,017.38. This represents a 2.59% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website.

Definium Therapeutics Stock Up 0.4%

Shares of NASDAQ DFTX opened at $44.95 on Friday. The company’s 50-day simple moving average is $24.59 and its 200-day simple moving average is $19.36. Definium Therapeutics, Inc. has a 52-week low of $6.40 and a 52-week high of $47.01. The firm has a market cap of $4.48 billion, a price-to-earnings ratio of -18.05 and a beta of 2.37. The company has a quick ratio of 4.69, a current ratio of 4.69 and a debt-to-equity ratio of 0.15.

Definium Therapeutics (NASDAQ:DFTX) last released its earnings results on Friday, May 8th. The company reported ($0.71) EPS for the quarter, missing analysts’ consensus estimates of ($0.48) by ($0.23). Equities analysts predict that Definium Therapeutics, Inc. will post -2.29 EPS for the current fiscal year.

Key Headlines Impacting Definium Therapeutics

Here are the key news stories impacting Definium Therapeutics this week:

• Positive Sentiment: Definium said its Phase III depression program delivered positive results, a key catalyst that can support optimism about eventual approval and commercialization. Definium raises $805 million after positive Phase III depression data
• Positive Sentiment: The company closed an upsized public offering, raising $805 million, which strengthens its balance sheet and reduces near-term financing risk. Definium Therapeutics Announces Closing of $805 Million Upsized Public Offering
• Neutral Sentiment: Several insiders, including the CEO and CFO, sold shares at $45.03. Insider selling can sometimes pressure sentiment, but the transactions were relatively small compared with their remaining holdings. CEO insider filing
• Neutral Sentiment: Market commentary and analyst writeups also pointed to the stock’s sharp move higher after the Phase III news, reinforcing the view that investors are reacting to the clinical-data catalyst. Why Definium Therapeutics, Inc.’s (DFTX) Stock Is Up 15.35%
• Negative Sentiment: Heavy insider selling from multiple executives may temper enthusiasm, as some investors could interpret it as a sign management views the stock as fully valued near recent highs.

Hedge Funds Weigh In On Definium Therapeutics

A number of institutional investors and hedge funds have recently added to or reduced their stakes in DFTX. Russell Investments Group Ltd. grew its holdings in Definium Therapeutics by 110.4% in the 2nd quarter. Russell Investments Group Ltd. now owns 3,817 shares of the company’s stock valued at $25,000 after buying an additional 2,003 shares in the last quarter. BNP Paribas Financial Markets raised its holdings in shares of Definium Therapeutics by 56.0% during the 2nd quarter. BNP Paribas Financial Markets now owns 8,417 shares of the company’s stock worth $55,000 after acquiring an additional 3,020 shares during the period. Flagship Harbor Advisors LLC acquired a new position in shares of Definium Therapeutics during the 4th quarter valued at about $117,000. FNY Investment Advisers LLC acquired a new position in shares of Definium Therapeutics during the 3rd quarter valued at about $107,000. Finally, Caxton Associates LLP purchased a new stake in shares of Definium Therapeutics in the third quarter valued at about $126,000. Institutional investors and hedge funds own 27.91% of the company’s stock.

Wall Street Analysts Forecast Growth

DFTX has been the topic of several research reports. Canaccord Genuity Group set a $60.00 target price on Definium Therapeutics in a research report on Monday. JonesTrading boosted their price target on Definium Therapeutics from $61.00 to $74.00 and gave the stock a “buy” rating in a research report on Wednesday. Robert W. Baird increased their price objective on Definium Therapeutics from $37.00 to $57.00 and gave the company an “outperform” rating in a research note on Tuesday. Citigroup restated a “buy” rating on shares of Definium Therapeutics in a report on Monday. Finally, Oppenheimer set a $60.00 target price on shares of Definium Therapeutics and gave the stock an “outperform” rating in a research note on Monday. Two analysts have rated the stock with a Strong Buy rating, fourteen have given a Buy rating and one has given a Sell rating to the stock. According to data from MarketBeat, the company presently has a consensus rating of “Buy” and an average target price of $47.08.

Definium Therapeutics Company Profile

Definium Therapeutics, Inc, a clinical stage biopharmaceutical company, develops novel products to treat brain health disorders. The company’s lead product candidates include MM120, which is in phase 3 for the treatment of generalized anxiety disorder and attention deficit hyperactivity disorder; and DT402, a R-enantiomer of 3,4-methylenedioxymethamphetamine, which is in phase 2a clinical trials for the treatment of core symptoms of autism spectrum disorder. The company was formerly known as Mind Medicine (MindMed) Inc and changed its name to Definium Therapeutics, Inc in January 2026.